Reaching the right audience is a critical decision. Use the system that does the work for you. Journals & Congresses helps you compare your options on the data points most important to you in making your decision. Get a ...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
How will NICE fare in a post-Brexit world?
In this article, ICON experts Caroline Delaitre-Bonnin, Emmanuel Lacharme and Manpreet Sidhu, consider how the UK drug pricing group, NICE, will be impacted post-Brexit.
-
Data Science: transforming the future of clinical trials
Gerard Quinn, VP of IT Innovation & Informatics, offers insights on the use of Machine Learning and Artificial Intelligence in clinical trials, and the potential benefits and challenges for CROs and sponsors (pages 16-17).
-
Real world evidence and the patient experience: Involving rare disease patients for successful trials
ICON's William C Maier and Maggie Adamski discuss case studies from their line of work, and how real world evidence can support those suffering with rare diseases around the world.
-
Two key questions about payer strategies in 2021
An interview with market access experts, including ICON's John Sliwka, on what they expect to see changing in the payer landscape in the coming years in the US market with the new Biden administration taking place.
-
Proving long-term value in advanced therapies: Digital technologies can measure durability of effect
This article by Marie McCarthy and Bob Swann discusses how robust assessments based on digital data are a means of reducing the uncertainty that HTA bodies and payers face in making decisions around advanced therapy medicinal products.
-
Global collaboration: Irish company ICON on scaling up COVID-19 vaccine trials
An interview in which Steve Cutler gives a short overview of ICON and describes the company’s role in the Pfizer/BioNTech trial, explaining how the FDA played a critical role in expediting regulatory approvals.
-
A selection of thought leadership materials from ICON experts on Decentralised & Hybrid Clinical Trials
-
The effect of Covid-19 solutions on the clinical trials process
Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership.
-
-
The Irish Times Business Person of the Month: Steve Cutler
ICON CEO Steve Cutler has been chosen as The Irish Times Business Person of the Month for February 2021.
